Open Access

Pegfilgrastim‑induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report

  • Authors:
    • Haruko Takuwa
    • Wakako Tsuji
    • Tomoyuki Goto
    • Takashi Otsuji
    • Fumiaki Yotsumoto
  • View Affiliations

  • Published online on: August 7, 2019     https://doi.org/10.3892/mco.2019.1907
  • Pages: 371-375
  • Copyright: © Takuwa et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dose‑dense (DD) chemotherapy is a treatment option for patients with high‑risk premenopausal breast cancer. Pegfilgrastim may be administered as prophylaxis against the development of febrile neutropenia and enables the continuation of the DD schedule; however, it is associated with adverse effects, including bone and muscle pain and fatigue. We herein describe our experience with pegfilgrastim administration alongside DD chemotherapy in a patient with breast cancer. A 29‑year‑old female patient was diagnosed with locally advanced breast cancer during lactation. The patient was diagnosed with cT2N1M0, stage IIB triple‑negative breast cancer and underwent four cycles of DD chemotherapy with epirubicin plus cyclophosphamide, followed by four cycles of docetaxel (DTX) every 2 weeks preoperatively, with 3.6 mg pegfilgrastim administered subcutaneously on day 3 of each cycle. The absolute neutrophil count (ANC) was 2,700, 8,400, 11,100, 13,300 and 15,000/mm3 on day 1 of each cycle. The patient experienced fatigue after each pegfilgrastim injection and was considered to be a high responder to pegfilgrastim. Therefore, 1.8 mg pegfilgrastim on day 3 of the first DD‑DTX cycle was recommended. On day 1 of the second cycle, the ANC was 13,090/mm3. The patient experienced less fatigue after the administration of 1.8 mg pegfilgrastim, but there was a significant decline in her performance status. As there is currently no evidence of pegfilgrastim dose reduction to below 1.8 mg, pegfilgrastim was omitted on day 3. On day 14, the patient developed viral enteritis, fever (38˚C), and an ANC of 297/mm3. Therefore, the third cycle was postponed. After 1 week, the patient's ANC recovered to 2,480/mm3 and she was administered the third cycle with 3.6 mg pegfilgrastim on day 3. Between January 2015 and March 2018, a total of 55 patients with breast cancer received chemotherapy with pegfilgrastim at the Shiga General Hospital. No patients other than the one presented herein experienced leukocytosis during chemotherapy. Although this was a rare complication, a dose of 1.8 mg pegfilgrastim was effective in palliating the patient's symptoms and preventing DD chemotherapy discontinuation.
View Figures
View References

Related Articles

Journal Cover

October 2019
Volume 11 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Takuwa, H., Tsuji, W., Goto, T., Otsuji, T., & Yotsumoto, F. (2019). Pegfilgrastim‑induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report . Molecular and Clinical Oncology, 11, 371-375. https://doi.org/10.3892/mco.2019.1907
MLA
Takuwa, H., Tsuji, W., Goto, T., Otsuji, T., Yotsumoto, F."Pegfilgrastim‑induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report ". Molecular and Clinical Oncology 11.4 (2019): 371-375.
Chicago
Takuwa, H., Tsuji, W., Goto, T., Otsuji, T., Yotsumoto, F."Pegfilgrastim‑induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report ". Molecular and Clinical Oncology 11, no. 4 (2019): 371-375. https://doi.org/10.3892/mco.2019.1907